866-997-4948(US-Canada Toll Free)

Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Aug 2017

Category :

Pharmaceutical

No. of Pages : 127 Pages

Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H2 2017, provides an overview of the Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) pipeline landscape.

H3N2 infections are caused by variant H3N2 virus which is an influenza virus. Symptoms include cough, sore throat, runny or stuffy nose, chills, nausea, vomiting, and/or diarrhea. Risk factors include age, chronic medical conditions like asthma, diabetes, heart disease, weakened immune systems, and neurological or neurodevelopment conditions. Treatment includes antiviral medications and antibiotics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Influenza A Virus, H3N2 Subtype Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenza A Virus, H3N2 Subtype Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 10, 6, 5, 18 and 3 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I and Preclinical stages comprises 2, 1, 1 and 3 molecules, respectively.

Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Influenza A Virus, H3N2 Subtype Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Influenza A Virus, H3N2 Subtype Infections (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Influenza A Virus, H3N2 Subtype Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Influenza A Virus, H3N2 Subtype Infections - Overview 8
Influenza A Virus, H3N2 Subtype Infections - Therapeutics Development 9
Pipeline Overview 9
Pipeline by Companies 10
Pipeline by Universities/Institutes 13
Products under Development by Companies 14
Products under Development by Universities/Institutes 18
Influenza A Virus, H3N2 Subtype Infections - Therapeutics Assessment 19
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Influenza A Virus, H3N2 Subtype Infections - Companies Involved in Therapeutics Development 27
AbbVie Inc 27
Adimmune Corp 28
AIMM Therapeutics BV 28
Aphios Corp 29
BioCryst Pharmaceuticals Inc 29
BiondVax Pharmaceuticals Ltd 30
Cadila Healthcare Ltd 30
Celltrion Inc 31
FluGen Inc 31
Glide Pharmaceutical Technologies Ltd 32
Inovio Pharmaceuticals Inc 32
Jiangsu Kanion Pharmaceutical Co Ltd 33
Johnson & Johnson 33
Medicago Inc 34
MedImmune LLC 34
Mucosis BV 35
NanoViricides Inc 35
Novavax Inc 36
OPKO Health Inc 36
Protein Sciences Corp 37
Sanofi Pasteur SA 38
Sarepta Therapeutics Inc 38
SK Chemicals Co Ltd 39
Takeda Pharmaceutical Company Ltd 39
VBI Vaccines Inc 40
Visterra Inc 40
Influenza A Virus, H3N2 Subtype Infections - Drug Profiles 41
APP-0205 - Drug Profile 41
APP-309 - Drug Profile 42
Aspidasept - Drug Profile 43
AT-0701 - Drug Profile 44
AV-5075S - Drug Profile 45
AV-5080 - Drug Profile 46
C-05 - Drug Profile 47
cetylpyridinium chloride - Drug Profile 48
CR-8043 - Drug Profile 49
CTP-27 - Drug Profile 50
Fluad (quadrivalent) - Drug Profile 51
Gamma-Flu - Drug Profile 52
influenza [strain A/H3N2] (monovalent) vaccine - Drug Profile 53
influenza [strain A/H3N2] vaccine - Drug Profile 54
influenza [strain A/H3N2] vaccine - Drug Profile 55
influenza [strain A/H3N2] vaccine - Drug Profile 56
influenza [strain A/H3N2v] vaccine - Drug Profile 57
influenza [strain A/H3N2v] vaccine - Drug Profile 58
influenza [strains A/H1N1 + A/H3N2 + A/H5N1] (virus like particle) vaccine - Drug Profile 59
influenza [strains A/H1N1 + A/H3N2 + A/H5N1] vaccine - Drug Profile 60
influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (quadrivalent) vaccine - Drug Profile 61
influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (quadrivalent) vaccine - Drug Profile 62
influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent) vaccine - Drug Profile 63
influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent, virus like particle) vaccine - Drug Profile 64
influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, split virion) vaccine - Drug Profile 67
influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, virus like particle) vaccine - Drug Profile 68
influenza [strains A/H1N1 + A/H3N2 + B] (quadrivalent) vaccine - Drug Profile 69
influenza [strains A/H1N1 + A/H3N2 + B] (quadrivalent) vaccine - Drug Profile 70
influenza [strains A/H1N1 + A/H3N2 + B] (split virion) vaccine - Drug Profile 71
influenza [strains A/H1N1 + A/H3N2 + B] (trivalent) vaccine - Drug Profile 72
influenza [strains A/H1N1 + A/H3N2 + B] (trivalent) vaccine - Drug Profile 76
influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile 77
influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile 78
influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile 79
influenza [strains A/H1N1 + A/H3N2 + B] vaccine - Drug Profile 80
influenza [strains A/H3N2 + A/H1N1] vaccine - Drug Profile 81
M-001 - Drug Profile 82
NBP-607 - Drug Profile 88
NEO-8877 - Drug Profile 89
NVINF-1 - Drug Profile 90
NVINF-2 - Drug Profile 95
Peptides for Influenza Infections - Drug Profile 98
peramivir - Drug Profile 99
pertussis [strain BPZE1] vaccine - Drug Profile 101
pimodivir hydrochloride - Drug Profile 103
PNSIA-28 - Drug Profile 106
radavirsen - Drug Profile 107
REDEE FLU - Drug Profile 109
Small Molecules for RSV and Influenza A Infections - Drug Profile 110
Small Molecules to Inhibit Neuraminidase for Influenza A Virus Infections - Drug Profile 111
VIS-410 - Drug Profile 112
Influenza A Virus, H3N2 Subtype Infections - Dormant Projects 115
Influenza A Virus, H3N2 Subtype Infections - Discontinued Products 116
Influenza A Virus, H3N2 Subtype Infections - Product Development Milestones 117
Featured News & Press Releases 117
Appendix 123
Methodology 123
Coverage 123
Secondary Research 123
Primary Research 123
Expert Panel Validation 123
Contact Us 123
Disclaimer 124

List of Tables
Number of Products under Development for Influenza A Virus, H3N2 Subtype Infections, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Influenza A Virus, H3N2 Subtype Infections - Pipeline by AbbVie Inc, H2 2017
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Adimmune Corp, H2 2017
Influenza A Virus, H3N2 Subtype Infections - Pipeline by AIMM Therapeutics BV, H2 2017
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Aphios Corp, H2 2017
Influenza A Virus, H3N2 Subtype Infections - Pipeline by BioCryst Pharmaceuticals Inc, H2 2017
Influenza A Virus, H3N2 Subtype Infections - Pipeline by BiondVax Pharmaceuticals Ltd, H2 2017
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Cadila Healthcare Ltd, H2 2017
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Celltrion Inc, H2 2017
Influenza A Virus, H3N2 Subtype Infections - Pipeline by FluGen Inc, H2 2017
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Glide Pharmaceutical Technologies Ltd, H2 2017
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Inovio Pharmaceuticals Inc, H2 2017
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Jiangsu Kanion Pharmaceutical Co Ltd, H2 2017
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Johnson & Johnson, H2 2017
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Medicago Inc, H2 2017
Influenza A Virus, H3N2 Subtype Infections - Pipeline by MedImmune LLC, H2 2017
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Mucosis BV, H2 2017
Influenza A Virus, H3N2 Subtype Infections - Pipeline by NanoViricides Inc, H2 2017
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Novavax Inc, H2 2017
Influenza A Virus, H3N2 Subtype Infections - Pipeline by OPKO Health Inc, H2 2017
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Protein Sciences Corp, H2 2017
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Sanofi Pasteur SA, H2 2017
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Sarepta Therapeutics Inc, H2 2017
Influenza A Virus, H3N2 Subtype Infections - Pipeline by SK Chemicals Co Ltd, H2 2017
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2017
Influenza A Virus, H3N2 Subtype Infections - Pipeline by VBI Vaccines Inc, H2 2017
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Visterra Inc, H2 2017
Influenza A Virus, H3N2 Subtype Infections - Dormant Projects, H2 2017
Influenza A Virus, H3N2 Subtype Infections - Discontinued Products, H2 2017

List of Figures
Number of Products under Development for Influenza A Virus, H3N2 Subtype Infections, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Targets, H2 2017
Number of Products by Stage and Targets, H2 2017
Number of Products by Mechanism of Actions, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Top 10 Molecule Types, H2 2017
Number of Products by Stage and Top 10 Molecule Types, H2 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *